Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:small_molecule
gptkb:drug |
| gptkbp:administeredBy |
gptkb:tablet
|
| gptkbp:ATCCode |
none (as of 2024)
|
| gptkbp:CASNumber |
1616392-12-2
|
| gptkbp:clinicalTrialPhase |
Phase 3
MANIFEST study MANIFEST-2 study |
| gptkbp:developedBy |
gptkb:Constellation_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C25H25ClN4O2S
|
| gptkbp:intendedUse |
gptkb:cancer
|
| gptkbp:investigatedBy |
gptkb:myelofibrosis
|
| gptkbp:mechanismOfAction |
BET inhibitor
|
| gptkbp:molecularWeight |
480.01 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
pelabresib
|
| gptkbp:target |
bromodomain and extra-terminal motif proteins
|
| gptkbp:bfsParent |
gptkb:Constellation_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|
| http://www.w3.org/2000/01/rdf-schema#label |
CPI-0610
|